Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline

Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.
Eli Lilly and Calytrix Bio announced on 16 November 2026 that they had signed a definitive acquisition agreement under which Calytrix shareholders may receive up to $1.5 billion in cash, consisting of an undisclosed upfront payment and additional consideration linked to future clinical and regulatory milestones.
The acquisition would add Calytrix's lead preclinical biparatopic antibody targeting mutant calreticulin to Lilly's precision haematology pipeline, with development focused on essential thrombocythaemia and myelofibrosis; the maximum headline value is contingent rather than guaranteed, and the programme has not yet reached clinical development or received regulatory approval.
Field | Content |
Article Type | Deals |
Acquirer | Eli Lilly |
Target Company | Calytrix Bio |
Deal Type | Definitive acquisition agreement |
Announcement Date | 16 November 2026 |
Transaction Status | Agreed |
Maximum Potential Consideration | Up to $1.5 billion |
Payment Currency | US dollars |
Payment Form | Cash |
Upfront Payment | Undisclosed |
Contingent Consideration | Clinical and regulatory milestone payments |
Guaranteed Upfront Value | Not disclosed |
Lead Programme | Mutant calreticulin-targeting antibody |
Lead Programme Development Stage | Preclinical |
Drug Modality | Biparatopic antibody |
Molecular Target | Mutant calreticulin |
Target Abbreviation | Mutant CALR |
Therapeutic Area | Haematology |
Disease Focus One | Essential thrombocythaemia |
Disease Focus Two | Myelofibrosis |
Disease Category | Myeloproliferative neoplasms |
Development Strategy | Precision targeting of disease-associated mutant calreticulin |
Clinical-Stage Asset Included | Not according to supplied summary |
Approved Medicine Included | No |
What Happened | Eli Lilly agreed to acquire Calytrix Bio and its preclinical mutant calreticulin antibody programme. |
Why It Matters | The acquisition strengthens Lilly's early-stage pipeline for rare blood disorders with significant unmet treatment needs. |
Scientific Significance | The programme targets mutant calreticulin, a disease-associated molecular alteration in certain myeloproliferative neoplasms. |
Strategic Significance | Expands Lilly's precision haematology research and development capabilities. |
Financial Significance | Shareholders may receive up to $1.5 billion subject to milestone achievement. |
Financial Clarification | The total potential value is not a disclosed upfront acquisition payment. |
Development Clarification | The lead programme remains preclinical, and efficacy in patients has not been established. |
Key Takeaway | Lilly plans to acquire Calytrix Bio for up to $1.5 billion to expand its mutant CALR-targeted haematology pipeline. |
What to Watch | Acquisition completion, preclinical progress, first-in-human development plans and milestone achievements. |
Primary Source | Calytrix Bio |
Primary Source URL | https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html |
Submitted Source | Reuters |
Submitted Source URL | https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-buy-calytrix-bio-up-15-billion-2026-11-16/ |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments